Zachary Klaassen speaks with Pedro Barata about a publication examining transcription profiles in renal cell carcinoma. The discussion explores the evolution from DNA-based to RNA-based genomic analysis in RCC, focusing on their study of over 600 patients’ gene expression signatures across different RCC subtypes. Dr. Barata emphasizes that non-clear cell RCC comprises biologically distinct cancers requiring individual approaches rather than a unified treatment strategy. The research reveals distinct gene expression patterns between clear cell and non-clear cell subtypes, with clear cell showing overexpression of angiogenesis signatures while non-clear cell subtypes demonstrate increased cell cycle, fatty acid oxidation, and pentose phosphate signaling. While these transcriptomic findings aren’t yet ready for clinical application, they may inform future trial designs and treatment decisions, particularly in combination therapy approaches with immunotherapy and TKIs.

Source – UroToday